首页 | 本学科首页   官方微博 | 高级检索  
     


Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma
Authors:Matthew J. Ahearne  Kaljit Bhuller  Roger Hew  Hazem Ibrahim  Kikkeri Naresh  Simon D. Wagner
Affiliation:1. Department of Cancer Studies and Molecular Medicine, Ernest and Helen Scott Haematology Research Institute and MRC Toxicology Unit, University of Leicester, Lancaster Road, Leicester, LE1 9HN, UK
2. Department of Haematology, Leicester Royal Infirmary, Leicester, LE1 5WW, UK
3. Department of Histopathology, Leicester Royal Infirmary, Leicester, LE1 5WW, UK
4. Department of Histopathology, Imperial College Healthcare NHS Trust, Hammersmith Hospital Campus, Du Cane Road, London, W12 0HS, UK
5. MRC Toxicology Unit, University of Leicester, Room 323, Hodgkin Building, Lancaster Road, Leicester, LE19HN, UK
Abstract:The role of the microenvironment in high-grade lymphoma is not well defined. In this report, we employ immunohistochemistry to characterise programmed death-1 (PD-1/CD279) and FoxP3 expression in 70 cases of diffuse large B-cell lymphoma (DLBCL). PD-1 is a surface marker characteristic of follicular helper T-cells whilst FoxP3 is characteristic of Tregs. We demonstrate variable infiltration with CD4+ T-cells (<10 to >50 % of all lymph node cells) and PD-1hi cells (0.1 to 1.5 % of all cells). CD4+ T-cells can be distributed in clusters or more diffusely and PD-1hi cells, but not FoxP3+ cells, are found in rosettes around lymphoma cells. Cases with high CD4+ T-cell numbers tended to have higher numbers of both PD-1hi and FoxP3+ cells. Cases with total CD4+ T-cell, PD-1hi and FoxP3+ numbers above the median associate with better clinical outcome. Overall, we demonstrate that infiltration by CD4+ T-cells, including both FoxP3+ and PD-1hi subsets, correlates with prognosis in DLBCL. In distinction to previous reported series, patients (91 %) were treated with rituximab-containing regimens, suggesting that the effects of CD4+ T-cell infiltration are maintained in the rituximab era. This work suggests that determinants of total CD4+ T-cell infiltration, either molecular characteristics of the lymphoma or the patients’ immune system, and not individual T-cell subsets, correlate with clinical outcome.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号